Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/actinium-highlights-ability-of-iomab-b-to-overcome-high-risk-tp53-mutation-resulting-in-significant-improvement-in-overall-survival-in-patients-with-active-relapsed-refractory-aml-at-the-european-bone-marrow-transplant-annual-meet-302120902.html
https://www.prnewswire.com/news-releases/actinium-announces-iomab-b-phase-3-sierra-trial-results-demonstrating-survival-benefit-in-high-risk-relapsed-or-refractory-acute-myeloid-leukemia-patients-with-tp53-mutations-accepted-for-oral-presentation-at-the-50th-european-bon-302104430.html
https://www.prnewswire.com/news-releases/actinium-announces-clinical-trial-to-study-iomab-act-targeted-radiotherapy-conditioning-with-leading-fda-approved-commercial-car-t-cell-therapy-302098890.html
https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-launches-actinium-225-focused-strategic-initiative-to-leverage-proprietary-cyclotron-based-manufacturing-technology-to-address-growing-market-demand-302084842.html
https://www.prnewswire.com/news-releases/actinium-announces-iomab-b-markedly-increases-long-term-survival-in-patients-65-years-or-older-with-active-relapsed-or-refractory-aml-in-the-phase-3-sierra-trial-at-the-2024-tandem-meetings--transplantation--cellular-therapy-mee-302070665.html
https://www.prnewswire.com/news-releases/actinium-highlights-improved-survival-with-iomab-b-in-tp53-positive-relapsed-refractory-acute-myeloid-leukemia-patients-in-the-sierra-trial-and-other-presentations-at-the-2024-tandem-meetings--transplantation--cellular-therapy-m-302069633.html
https://www.prnewswire.com/news-releases/actinium-announces-acceptance-of-five-abstracts-for-presentation-at-the-2024-tandem-meetings--transplantation--cellular-therapy-meetings-of-astct-and-cibmtr-302024287.html
https://www.prnewswire.com/news-releases/actinium-announces-iomab-b-produces-high-response-rates-and-significant-improvement-in-overall-survival-in-relapsed-refractory-aml-patients-with-active-disease-overcoming-tp53-mutation-302011016.html
https://www.prnewswire.com/news-releases/actiniums-four-presentations-at-ash-highlight-the-positive-outcomes-for-iomab-b-and-actimab-a-in-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-302011000.html
https://www.prnewswire.com/news-releases/actinium-to-highlight-broad-potential-of-targeted-radiotherapies-iomab-b-and-actimab-a-for-relapsed-or-refractory-and-elderly-acute-myeloid-leukemia-patients-at-the-65th-ash-annual-meeting--exposition-302010070.html